drugset / Trial / NCT03254368
Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of the study drug ZGN-1061 in participants with type 2 diabetes.
Timeline
- Start
- 2017-09-12
- Primary completion
- 2018-11-12
- Completion
- 2019-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACLIMOSTAT | Small molecule | 0.05 mg | Subcutaneous |
| Subject | ACLIMOSTAT | Small molecule | 0.3 mg | Subcutaneous |
| Subject | ACLIMOSTAT | Small molecule | 0.9 mg | Subcutaneous |
| Subject | ACLIMOSTAT | Small molecule | 1.8 mg | Subcutaneous |